Nordic Life Science 1
PHOTO TIMOTHY GILBERT PHOTO JENNY LAGERQVIST 02 0
1. INTERVIEW JOHAN LIWING XNK Therapeutics recently secured a private placement of 132 million SEK, enabling progress of the company’s development of new autologous NK cell-based therapies. READ MORE ON PAGE 46 02. GROWING A COMPANY What are the secret ingredients for successful company growth within life sciences? What lessons can we learn from the journeys, progress, setbacks and challenges of other Nordic companies? READ MORE ON PAGE 50 03. Q&A: NIKOLAJ SØRENSEN Patent, pricing, production, and partnerships – these are the four Ps that companies must keep front and center for a successful market entry. READ MORE ON PAGE 60 04. COLUMN HANS ENGBLOM Most listed Swedish biotech companies have cash and financing that is sufficient until 2023 or longer. The few who don’t, should probably hurry while there is time. READ MORE ON PAGE 62